NEW YORK (GenomeWeb) – Several independent researchers last week shared promising results of their work using the genome-editing tool CRISPR/Cas9 to advance treatments for Duchenne muscular dystrophy.

In a group of three studies published in the Jan. 1 issue of Science, researchers found that after viral delivery into muscle tissue or blood, CRISPR/Cas9 was able to excise disease-associated exons from the dystrophin gene, and improve the symptoms of mice with a rodent version of the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.